Abstract
Pancreas transplantation offers a functional cure for many patients suffering from diabetes mellitus. Although the outcomes of pancreas transplants were originally plagued with high rates of acute cellular rejection, innovations in immunosuppression regimens over the last two decades have helped steadily improve the graft survival of pancreas transplants. This review surveys the latest trends in immunosuppressive management for pancreas transplant recipients, discussing the controversies and weighing the evidence supporting induction therapy, steroid avoidance/withdrawal, mTOR inhibitors, and new regimens based on costimulatory blockade agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
